Kornimate/medical-research-clean huggingface dataset:
genetic polymorphisms in idiopathic pulmonary fibrosis (ipf)

Conditions: Pulmonary Fibrosis

Summary: the purposes of this study are: * to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; * to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.

idiopathic pulmonary fibrosis (ipf) is a disease of unknown etiology that is characterized by the insidious development of lung fibrosis ultimately leading to distortion of the lung architecture, respiratory failure, and death. ipf is one of several entities associated with pulmonary fibrosis called the idiopathic interstitial pneumonias (iip). based on the histopathologic features of the fibrotic process, it is possible to identify four distinct entities: usual interstitial pneumonia (uip) (synonymous with ipf), nonspecific interstitial pneumonia (nsip), desquamative interstitial pneumonia dip), and acute interstitial pneumonia (aip) (hamman-rich lung). each type appears to have different clinical progression and a different response to anti-inflammatory therapy. our overall objective is to elucidate the molecular pathogenesis of ipf (uip) by identifying factors that determine host susceptibility to this disease. we hypothesize that patients who develop pulmonary fibrosis, have a genetic propensity to abnormal lung repair that leads to fibrosis after acute lung injury. we further hypothesize that these genetic susceptibilities may determine if the pathologic process in the lung after an insult becomes uip, aip, nsip, or dip. to explore these hypotheses we propose to characterize the genetic polymorphisms in candidate genes involved in inflammation, matrix turnover, fibroblast proliferation and differentiation, and epithelial cell proliferation; and to correlate this with indices of disease progression.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function testing, chest x-ray, and computed tomography (ct) scans. * adult patients who are seeking treatment at the dorothy p. and richard p. simmons center for interstitial lung disease. exclusion criteria: * under 18 years of age * non-fibrotic ild

Keywords: "lung[a04.400]"
video-based games for upper limb rehabilitation in cerebral palsy

Conditions: Cerebral Palsy; Rehabilitation

Summary: the aim of the present study is to compare the effects of neurodevelopmental treatment (ndt)-based upper limb rehabilitation and video-game based therapy (vgbt) with nintendo® wii and lmc games on upper extremity functions in patients with cerebral palsy (cp).

the investigators hypothesized that vgbt using the nintendo® wii and lmc would be a usable tool to train manual dexterity in patients with cp as comprehensive and holistic therapy. the ndt program for both groups will be routinely applied according to each child's individual needs and included tonus regulation, support of sensation, perception and motor development for gross motor function. the two different patient-centered rehabilitation programs will be conducted with an average of one hour sessions three times a week for 8 weeks in both groups. the two different patient-centered programs will be as vgbt with nintendo® wii and lmc games (group i) and ndt-based upper limb rehabilitation (group ii).

Eligibility criteria:
inclusion criteria: the health committee report has received a cp diagnosis * being between 5-18 years of age * according to modifiye ashworth scale (mas), upper extremity spasticity (0), (1), (1+) * ability to adapt to exercises (according to the health report mental level normal or "mild mental retardation" exclusion criteria: * botulinium toxin (botox) injection for the upper extremity in the last 6 months * does not have epileptic epilepsy * any person who has been diagnosed as having any absence of a cardiac or orthopedic condition * admission of family treatment
insulin glargine first line vs metformin in type 2 diabetic subjects

Conditions: Type 2 Diabetes

Summary: comparison of efficacy and safety of glargine insulin and metformin as first line drug of patients insufficiently treated with lifestyle intervention. so far treatment also algorithm with lifestyle and metformin has not been evaluated in patients with type 2 diabetes and hba1c greater or equal 7 % and lower than 8.1%.besides hba1c postprandial glucose excursion and glycemic variability as determinants of oxidative stress will be measured by continuous glucose measurement(cgm). further more cgm will reveal risk of hypoglycemia at night. as secondary objectives effect on endothelial function, renal function and biomarkers of low great inflammation will be evaluated. so far only scarce information on face to face comparison in ealy diabetes exists.


Eligibility criteria:
inclusion criteria: * early type 2 diabetes (lower than 5 years known) * male and female(35 to 75 years) * hba1c 7 to 8 %, if drug naive and \<= 8.5 with previous oad intake * informed consent exclusion criteria: * any treatment more than one oad at the same time * treatment with one oad \< 6 weeks time * insulin treatment * acute coronary syndrome \< 6 months * severe liver disease * alcohol abuse or drug addiction * severe kidney disease * acute critical illness with renal impairment * i.v. application of iodine * ketoacidosis * acute or chronic illness witch may lead to hypoxia or cardial failure * allergy against one of the drugs * deficit in compliance or cooperation * pregnancy or breast feeding * women in fertile age without accepted contraceptive
measurement of retinal venous pressure in chronic low-oxygen environment

Conditions: Healthy

Summary: the hypothesis is that the pressure in the retinal veins increases from chronic lack of oxygen and leads to decreased blood flow. on the basis of high altitude mountaineering this hypothesis should be verified. at the same time the adaptation capacity of the blood circulation should be analyzed, and a relationship to mountain sickness should be found.

conduct a field study to describe and quantify the retinal venous pressure (rvp) in healthy volunteers under conditions of controlled chronically reduced ambient pressure and oxygen partial pressure in the mountains. obtaining indications regarding the adaptation of the retinal vascular system behavior to controlled, long-term hypoxic changes. comparisons with blood pressure, pulse, oxygen saturation level and the appearance of symptoms of acute mountain sickness are made in order to obtain a better understanding of the development of high altitude illness.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * eye diseases * systemic diseases * term medication (except contraceptives) * pregnancy * allergies to the ingredients alcain, tropicamide and phenylephrine

Keywords: retinal venous pressure (rvp) chronically reduced ambient pressure oxygen partial pressure mountain sickness
comprehensive immune-landscape in localized colorectal cancer

Conditions: Colorectal Cancer; Immune Landscape

Summary: surgery still remains the mainstay of treatment for localized colorectal cancer. however, nearly 30% of patients with localized colorectal cancer (stage ii and stage iii) will present with recurrence. tumor progression is mediated by both intrinsic genetic changes and by extrinsic epigenetic and host environmental factors, including interactions with the immune system. several studies demonstrated that tumor infiltrating memory t-cells and type, density and location of infiltrating t cells are better predictors of disease-free survival in patients with crc compared to the standard tnm staging. these data suggest that tumor invasion and progression are more accurately predicted by immune response in the primary tumor. in addition, mismatch repair (mmr)-deficient tumors are characterized a priori by a higher frequency of tumor infiltrating lymphocytes and are associated with significantly improved prognosis. recently, stotz et al showed that the preoperative lymphocyte to monocyte ratio in peripheral blood samples predicts clinical outcome in patients with stage iii colon cancer. so far there is no comprehensive analysis of the immune-landscape in crc. the aim of the current project is to identify a comprehensive panel of immunomarkers in localized colorectal cancer (stage ii and stage iii) applicable for the detection of patients at high risk of recurrence. for the first time, specific tumor-infiltrating immune cells, mismatch repair protein expression in tumor tissue and preoperative blood based inflammatory markers from routine blood counts in corresponding peripheral blood samples and known clinicopathological features will be correlated with outcome in 300 localized crc patients.


Eligibility criteria:
inclusion criteria: * male and female patients ≥ 18 years of age; * formalin fixed paraffin embedded (ffpe) tissue samples of stage ii and stage iii colorectal cancer patients consecutively enrolled at the division of clinical oncology, department of med.university of graz (graz, austria) between 1995 - 2011 exclusion criteria: * male and female patients \< 18 years of age
early saline irrigation to decrease post-operative endoscopic debridement

Conditions: Chronic Rhinosinusitis

Summary: nasal saline is a common treatment adjunct in the post-operative setting for endoscopic sinus surgery. however, the ideal timing and quantity of irrigation in the early post-operative period remains unknown. proposed benefits of early, large volume irrigation include removal and softening of crusts, resulting in improved mucociliary clearance. the potential benefit of early large volume saline irrigation on post-operative day three to ease or reduce the need for early post-operative debridement has not been studied.


Eligibility criteria:
inclusion criteria: * adult patients * diagnosis of crs with or without polyposis * undergoing bilateral endoscopic sinus surgery * availability of pre-operative ct paranasal sinuses exclusion criteria: patients with diagnosis of: * primary ciliary dyskinesia * immunodeficiency * cystic fibrosis

Keywords: endoscopic sinus surgery post-operative irrigation pain debridement
an extension protocol for virologically suppressed subjects who successfully completed pro140_cd03 study

Conditions: HIV-1-infection

Summary: this study is a phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing pro 140 350mg, 525mg, or 700mg sc monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects. consenting subjects will continue weekly pro 140 350mg, 525mg, or 700mg monotherapy during the treatment extension phase with the one week overlap of existing retroviral regimen and pro 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.

the objective is to assess the long-term safety of using pro 140 350mg, 525mg, or 700mg sc as single-agent maintenance therapy for the chronic suppression of ccr5-tropic hiv-1 infection.

Eligibility criteria:
inclusion criteria: 1. subjects who have completed 48 weeks of treatment in pro140_cd03 study. 2. last known plasma hiv-1 rna \< 50 copies/ml within pro140_cd03 study. 3. both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \[male condom, female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). females of childbearing potential must have a negative serum pregnancy test at screening visit and negative urine pregnancy test prior to receiving the first dose of study drug. 4. willing and able to participate in all aspects of the study, including use of sc medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent. exclusion criteria: 1. not currently enrolled in pro140_cd03 study. 2. any active infection or malignancy requiring acute therapy (with the exception of local cutaneous kaposi's sarcoma). 3. females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study. 4. subjects weighing \< 35kg. 5. history of anaphylaxis to any oral or parenteral drugs. 6. history of bleeding disorder or patients on anti-coagulant therapy (except aspirin). note: subjects with well-controlled bleeding disorder while on stable anti-coagulant therapy dose with documented stable inrs can be enrolled as per discretion of the investigator. 7. any other clinical condition that, in the investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
investigating the efficacy of a dentifrice in providing long term relief from dentinal hypersensitivity

Conditions: Dentine Hypersensitivity

Summary: clinical studies have demonstrated long term relief from dentine hypersensitivity with twice daily brushing of a toothpaste containing stannous fluoride in comparison to marketed (negative) controls. the aim of this study is to evaluate the effectiveness of a stannous fluoride dentifrice in the treatment of dentinal hypersensitivity compared to a marketed (negative) control, over a period of 56 days (8 weeks) with twice daily brushing.


Eligibility criteria:
inclusion criteria: * participants with self-reported history of dentinal hypersensitivity lasting more than 6 months but not more than 10 years. * participants with minimum of 20 natural teeth. * at screening, a minimum of two accessible teeth (incisors, canines, premolars) that meet all of the following criteria. 1. teeth showing signs of facial/cervical gingival recession and/or signs of erosion or abrasion. 2. teeth with gingival index score ≤1 and a clinical mobility of ≤1. 3. teeth that are determined to be sensitive by the subject following a 1 second air blast to the cervical margin. exclusion criteria: * presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes. * any condition which, in the opinion of the investigator, causes dry mouth. * tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening. * participant using of a desensitising dentifrice within 6 weeks of screening
saphenous nerve block after tibial plateau orif

Conditions: Tibial Plateau Fracture; Pain, Postoperative

Summary: fractures of the tibial plateau, while very painful, typically do not receive nerve blocks. this is because of a concern that the numbness from a nerve block would "mask" the typically painful symptoms of compartment syndrome, a condition that can lead to a permanent loss of function of the injured limb. our study aims to evaluate the effectiveness of saphenous nerve block for pain management after surgical repair of a tibial plateau fracture. based on cadaver studies and our clinical experience, we suspect that the saphenous nerve contributes to pain sensations of the tibial plateau and will not mask the pain from a compartment syndrome. in summary, while saphenous nerve block represents a safe option after tibial plateau open reduction internal fixation (orif), we aim to evaluate its effectiveness in this patient population.


Eligibility criteria:
inclusion criteria: * tibial plateau fracture presenting for orif * age greater than or equal to 18 years exclusion criteria: * other concomitant life-threatening injuries * history of chronic pain prior to tibial plateau orif * age \<18 years old * pregnancy * any condition impairing patient's ability to consent to participation in study * existing condition contraindicating a nerve block * non-english speaking
evaluation of biomarkers in human synovial fluid

Conditions: Osteoarthritis

Summary: osteoarthritis is a condition that causes joints in the human body to deteriorate over time. this condition affects more than 250 million people around the globe. currently, the goal of treating osteoarthritis involves reducing the severity and pain that results from the disease. the ultimate goal of this study is to identify patients with pre-arthritic joints (before symptoms or disease characteristics appear) in an effort to find and use treatments that stop or slow the disease. joints are filled with a naturally occurring liquid known as synovial fluid. molecules (biomarkers) and genetic expression of various cell types within synovial joint fluid may serve as measures of onset and progression of osteoarthritis. these samples have the potential to improve diagnosis, classification, and treatment, possibly changing the natural history of this debilitating disease. the purpose of this study is to develop a collection of synovial fluid samples from the shoulder, hip and knee for the analysis of biomarkers and cellular and genetic components therein to better understand the pre-arthritic joint, progression to disease, and response to interventions.


Eligibility criteria:
inclusion criteria: 1. adult patients ( \> 18 years old) 2. patient is eligible for general anesthesia and either arthroscopy or arthroplasty. 3. patient needs standard of care arthroscopy or arthroplasty of either shoulder, hip or knee joint for osteoarthritis or prearthritic conditions. 4. patient must have signed an irb approved informed consent document for the arthrocentesis procedure which will be performed during the arthroscopic or arthroplastic procedure. exclusion criteria: 1. active joint infection within last 6 months. 2. previous arthroplasty in the joint undergoing arthroplasty 3. history of auto-immune arthropathies. 4. history of hiv or hepatitis c

Keywords: synovial fluid biomarkers
active injury management (aim) after pediatric concussion

Conditions: Brain Concussion

Summary: the proposed interventions of this study will determine the ideal discharge recommendations related to activity

the investigators will conduct a phase ii factorial clinical trial . the clinical trial will determine the benefit of prescribed low-intensity physical activity, behavioral management, or both, versus standard rest in acute (24-48 hrs) (moderate traumatic brain injury (mtbi) patients presenting to the pediatric emergency department (ed). low-intensity physical activity (i.e.10,000 steps/day) will be prescribed and monitored in the first week post-injury with an actigraph (fitbit®). behavioral management will be prescribed using a phone app referred to as mhealth (mobile health, specifically superbetter©) that promotes mental, physical, social, and emotional resilience. this randomized clinical trial will have four treatment groups: 1) activity, 2) mhealth, 3) activity+mhealth, 4) rest. the primary study outcomes will be symptoms and recovery by 14 days. all subjects will be assessed via phone at 3-5 days and in person at 14 days. the secondary outcomes will be to determine the influence of interventions on comprehensive aspects of physiologic recovery and patient-centered outcomes; including symptoms at 3 days, neurocognitive, vestibular/ocular motor impairment at 14 days, pediatric quality of life measures, time to symptom resolution, and return to normal activity via phone survey at 1 and 2 months. the investigators will assess symptom, quality of life, and recovery outcomes based on treatment group assignment for all subjects and high-risk subjects.

Eligibility criteria:
inclusion criteria: * diagnosis of mtbi in the past 72 hours exclusion criteria: * patients having conditions otherwise which limit physical activity or neurocognitive assessment * do not have a smart phone * history of brain surgery or past moderate/severe tbi within the last 6 months, * substance abuse, * major psychiatric condition under ongoing treatment with medications, * vestibular disorder, * cardiac condition, * unable to provide consent/assent * previous enrollment in the study

Keywords: concussion
neoadjuvant finasteride for patients with non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. this information may be of benefit for future treatment strategies, prevention and control. in this study, the protein where testosterone binds, called the androgen receptor (ar), will be measured in samples from the patient's biopsy and surgical tumor samples. the investigators will look at a marker of how fast the cancer is growing (ki67) before using finasteride from your biopsy specimen. finasteride will be taken from the day of consent until the day of the patient's surgery. this marker will be measured again after using finasteride from the surgical specimen. the investigators will be looking for a decrease in the ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that this medication is blocking tumour growth.


Eligibility criteria:
inclusion criteria: * male * age \>18 * biopsy-proven non-small cell lung cancer * surgical intervention planned exclusion criteria: * current use of 5-alpha reductase inhibitor * previous diagnosis of prostate cancer * previous hypersensitivity to 5-alpha reductase inhibitor
acupuncture for patients with diarrhea-predominant ibs or functional diarrhea: a randomized controlled trial

Conditions: Diarrhea-predominant Irritable Bowel Syndrome; Functional Diarrhea

Summary: this trial is to assess the effectiveness of three types of acupuncture for patients with functional diarrhea comparing to a positive drug control.

outcome measurements: the frequency of bowel movement; the bristol stool scale; sf-36 evaluation

Eligibility criteria:
inclusion criteria: 1. diagnosed as diarrhoea-predominant irritable bowel syndrome according to rome iii criteria; 2. age between 18 and 65 years old; 3. did not take any medicine for bowel symptoms and attend other clinical research; 4. have inform consent signed. exclusion criteria: 1. diarrhea caused by diseases such as infection, etc. 2. patients can't express himself clearly or with mental diseases; 3. tumor and other infectious diseases; 4. with other serious diseases of cardiovascular, liver, kidney, digestive or blood system; pregnant women or planned to be pregnant.

Keywords: acupuncture loperamide functional diarrhea ibs